Grants from the Medical Research Endowment Fund provide pilot research funding that has the potential to develop into extramurally funded, scientifically significant research projects. Support is focused on new areas of research for young faculty investigators and new avenues of research for mature investigators.
Schinke’s research project is “Pre-Treatment mutational landscape of hematopoietic stem cells in therapy related myelodysplastic syndromes and acute myeloid leukemia.”
The goal of Schinke’s research is to understand the pathogenesis and influence
of cytotoxic treatment in therapy-related myelodysplatic syndromes (t-MDS) and acute myeloid leukemia (t-AML), both of which are not uncommon secondary diseases in patients with myeloma who have undergone high-dose chemotherapy.
Previous studies have shown the existence of t-MDS/t-AML clones prior to high-dose chemotherapy. However, the sample sizes were small, thereby limiting the investigation of the mutation landscape of the aberrant cells.
With the vast patient population and stored bone marrow samples at the Myeloma Institute, there is a unique opportunity to study hematopoietic stem cells procured from a large number of t-MDS/t-AML patients prior to their development of the secondary disease.
This will yield important information on pathogenesis and clonal evolution in t-MDS/t-AML.